Verification Pending — official Grants.gov candidate (posted)
PAR-25-059
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Official Grants.gov opportunity PAR-25-059 from National Institutes of Health. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.
FundingOfficial federal synopsis lists an award ceiling of 750,000; applicant-level applicability requires full-NOFO review.
Deadline2027-10-20 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.
Broad Eligibility
City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); County governments; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Special district governments; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Public and State controlled institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Private institutions of higher education; For profit organizations other than small businesses; Small businesses
Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-059
Official listed status: posted
Closing information: 2027-10-20 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 750,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); County governments; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Special district governments; Independent school districts; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal governments (Federally recognized); Public and State controlled institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Private institutions of higher education; For profit organizations other than small businesses; Small businesses
Federal synopsis
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.
Official Grants.gov opportunity and NOFO
From Funding to Implementation · School Health Solution
Turn school-health funding into a clinically capable care model.
Dr. Miltie N9+ can support clinician-directed remote exams in school settings, helping care teams move beyond video-only encounters when a funded program calls for stronger pediatric access.
Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
